The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy

Abstract

AbstractIntroductionSince the start of the COVID‐19 pandemic, data published on the immunogenicity of the SARS‐CoV‐2 BNT 162B2 vaccine in pediatric patients receiving renal replacement therapy are scant. Our primary objective is to study this population's humoral immune response to the COVID‐19 vaccine.MethodsPediatric kidney transplant recipients (PKTRs) and hemodialysis recipients (HR) at our center who received two doses of the SARS‐CoV‐2 BNT 162B2 vaccine were included. Transplant and HR who had PCR‐positive COVID‐19 infections during the study, regardless of their vaccine status, were also included. SARS‐CoV‐2 anti‐spike protein (S1/S2) IgG was measured after the second dose of the vaccine and after any PCR‐positive COVID‐19 infection as routine clinical practice. Data on demographics, induction, maintenance immunosuppressants, type of transplant, and posttransplant or dialysis duration were included.ResultsOf the 61 patients included, 19 were dialysis recipients who received two doses of vaccine without subsequent infection (HV), and 42 were kidney transplant recipients. All dialysis patients and 33 (78.6%) transplant recipients received two doses of the SARS‐CoV‐2 BNT 162b2 vaccine. A total of 33.3% (11/33) of the transplant recipients who received vaccination developed COVID‐19 infection (KTH) at a median time of 13 days after the second dose of vaccine. Nine transplant patients had pure COVID‐19 infection without vaccination (KTI). The seroconversion rate in the HV group was 94.7% (18/19) compared to 50% (11/22) in the kidney transplant vaccine recipients who did not develop subsequent COVID‐19 infection (KTV) (p < .001). The median S1/S2 IgG titers for the HV group were 400 AU/mL versus 15 AU/mL in the KTV group (p < .0001). There was no significant difference in the duration of the test from the second dose of the vaccine between HV and KTV (55 vs. 33.5 days, p = .095). The KTH had higher titers than KTV group (370 vs. 15 p < .0001). The median duration of the test after vaccination in the vaccine group and those with hybrid immunity was similar (35 vs. 33.5 days, p = .2).There were no clear predictors for seroconversion in the PKTRs. Natural infection alone was as good as the vaccine in eliciting humoral immune response.ConclusionThe humoral immune response to two doses of the SARS‐CoV‐2 BNT 162B2 vaccine in PKTRs without subsequent COVID‐19 infection is suboptimal compared to that in hemodialysis recipients and in PKTRs with hybrid immunity from both infection and vaccination.